Position in ABBV
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$244,845
+$33,228 QoQ
Shares Held
973
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
#3,809
of 4,167 holders
Holding Since
Jun 2022
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Cairn Investment Group, Inc. holds $15,565,541 across 7 Drug Manufacturers - General names. ABBV ranks #7 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
54,875 | $7,051,437 | |
| 2 | LLY |
ELI LILLY & Co
|
2,610 | $3,130,512 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
21,247 | $2,684,345 | |
| 4 | BIIB |
Biogen Inc.
|
8,043 | $1,737,770 | |
| 5 | NVO |
Novo Nordisk A S
|
9,333 | $447,424 | |
| 6 | JNJ |
Johnson & Johnson
|
1,060 | $269,208 | |
| 7 | ABBV |
AbbVie Inc.
This page
|
973 | $244,845 |
All Filings in ABBV
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $244,845 | 973 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $211,617 | 973 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $222,320 | 973 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $225,288 | 973 | Shares | Sole | 2025-10-28 | |
| 2022-12-31 | $401,116 | 2,482 | Shares | Sole | 2023-01-11 | |
| 2022-09-30 | $286,672 | 2,136 | Shares | Sole | 2022-10-13 | |
| 2022-06-30 | $366,818 | 2,395 | Shares | Sole | 2022-07-28 | |
| No filing history on record for this holder in this stock. | ||||||